216 related articles for article (PubMed ID: 21923736)
1. Variations in tissue selectivity amongst insulin secretagogues: a systematic review.
Abdelmoneim AS; Hasenbank SE; Seubert JM; Brocks DR; Light PE; Simpson SH
Diabetes Obes Metab; 2012 Feb; 14(2):130-8. PubMed ID: 21923736
[TBL] [Abstract][Full Text] [Related]
2. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide.
Sunaga Y; Gonoi T; Shibasaki T; Ichikawa K; Kusama H; Yano H; Seino S
Eur J Pharmacol; 2001 Nov; 431(1):119-25. PubMed ID: 11716850
[TBL] [Abstract][Full Text] [Related]
3. Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1.
Hansen AM; Christensen IT; Hansen JB; Carr RD; Ashcroft FM; Wahl P
Diabetes; 2002 Sep; 51(9):2789-95. PubMed ID: 12196472
[TBL] [Abstract][Full Text] [Related]
4. Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions.
Gribble FM; Reimann F
J Diabetes Complications; 2003; 17(2 Suppl):11-5. PubMed ID: 12623163
[TBL] [Abstract][Full Text] [Related]
5. Stoichiometry of sulfonylurea-induced ATP-sensitive potassium channel closure.
Dörschner H; Brekardin E; Uhde I; Schwanstecher C; Schwanstecher M
Mol Pharmacol; 1999 Jun; 55(6):1060-6. PubMed ID: 10347249
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic beta-cell K(ATP) channel activity and membrane-binding studies with nateglinide: A comparison with sulfonylureas and repaglinide.
Hu S; Wang S; Fanelli B; Bell PA; Dunning BE; Geisse S; Schmitz R; Boettcher BR
J Pharmacol Exp Ther; 2000 May; 293(2):444-52. PubMed ID: 10773014
[TBL] [Abstract][Full Text] [Related]
7. Taurine block of cloned ATP-sensitive K+ channels with different sulfonylurea receptor subunits expressed in Xenopus laevis oocytes.
Lim JG; Lee HY; Yun JE; Kim SP; Park JW; Suh SI; Jang BC; Cho CH; Bae JH; Kim SS; Han J; Park MJ; Song DK
Biochem Pharmacol; 2004 Sep; 68(5):901-10. PubMed ID: 15294453
[TBL] [Abstract][Full Text] [Related]
8. Nateglinide, a D-phenylalanine derivative lacking either a sulfonylurea or benzamido moiety, specifically inhibits pancreatic beta-cell-type K(ATP) channels.
Chachin M; Yamada M; Fujita A; Matsuoka T; Matsushita K; Kurachi Y
J Pharmacol Exp Ther; 2003 Mar; 304(3):1025-32. PubMed ID: 12604678
[TBL] [Abstract][Full Text] [Related]
9. Testing the bipartite model of the sulfonylurea receptor binding site: binding of A-, B-, and A + B-site ligands.
Winkler M; Stephan D; Bieger S; Kühner P; Wolff F; Quast U
J Pharmacol Exp Ther; 2007 Aug; 322(2):701-8. PubMed ID: 17495126
[TBL] [Abstract][Full Text] [Related]
10. Biomedical Informatics Approaches to Identifying Drug-Drug Interactions: Application to Insulin Secretagogues.
Han X; Chiang C; Leonard CE; Bilker WB; Brensinger CM; Li L; Hennessy S
Epidemiology; 2017 May; 28(3):459-468. PubMed ID: 28169935
[TBL] [Abstract][Full Text] [Related]
11. Potassium channel openers require ATP to bind to and act through sulfonylurea receptors.
Schwanstecher M; Sieverding C; Dörschner H; Gross I; Aguilar-Bryan L; Schwanstecher C; Bryan J
EMBO J; 1998 Oct; 17(19):5529-35. PubMed ID: 9755153
[TBL] [Abstract][Full Text] [Related]
12. Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular K(ATP) channels.
Stephan D; Winkler M; Kühner P; Russ U; Quast U
Diabetologia; 2006 Sep; 49(9):2039-48. PubMed ID: 16865362
[TBL] [Abstract][Full Text] [Related]
13. Sulfonylurea and non-sulfonylurea hypoglycemic agents: pharmachological properties and tissue selectivity.
Nagashima K; Takahashi A; Ikeda H; Hamasaki A; Kuwamura N; Yamada Y; Seino Y
Diabetes Res Clin Pract; 2004 Dec; 66 Suppl 1():S75-8. PubMed ID: 15563985
[TBL] [Abstract][Full Text] [Related]
14. Kir6.2-dependent high-affinity repaglinide binding to beta-cell K(ATP) channels.
Hansen AM; Hansen JB; Carr RD; Ashcroft FM; Wahl P
Br J Pharmacol; 2005 Feb; 144(4):551-7. PubMed ID: 15678092
[TBL] [Abstract][Full Text] [Related]
15. Interaction of the sulfonylthiourea HMR 1833 with sulfonylurea receptors and recombinant ATP-sensitive K(+) channels: comparison with glibenclamide.
Russ U; Lange U; Löffler-Walz C; Hambrock A; Quast U
J Pharmacol Exp Ther; 2001 Dec; 299(3):1049-55. PubMed ID: 11714894
[TBL] [Abstract][Full Text] [Related]
16. Interaction of a novel dihydropyridine K+ channel opener, A-312110, with recombinant sulphonylurea receptors and KATP channels: comparison with the cyanoguanidine P1075.
Felsch H; Lange U; Hambrock A; Löffler-Walz C; Russ U; Carroll WA; Gopalakrishnan M; Quast U
Br J Pharmacol; 2004 Apr; 141(7):1098-105. PubMed ID: 15023854
[TBL] [Abstract][Full Text] [Related]
17. Effect of repaglinide on cloned beta cell, cardiac and smooth muscle types of ATP-sensitive potassium channels.
Dabrowski M; Wahl P; Holmes WE; Ashcroft FM
Diabetologia; 2001 Jun; 44(6):747-56. PubMed ID: 11440368
[TBL] [Abstract][Full Text] [Related]
18. Sulfonylurea receptor 1 subunits of ATP-sensitive potassium channels and myocardial ischemia/reperfusion injury.
Lefer DJ; Nichols CG; Coetzee WA
Trends Cardiovasc Med; 2009 Feb; 19(2):61-7. PubMed ID: 19577714
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369A.
Lang VY; Fatehi M; Light PE
Pharmacogenet Genomics; 2012 Mar; 22(3):206-14. PubMed ID: 22209866
[TBL] [Abstract][Full Text] [Related]
20. Structural requirements of sulphonylureas and analogues for interaction with sulphonylurea receptor subtypes.
Meyer M; Chudziak F; Schwanstecher C; Schwanstecher M; Panten U
Br J Pharmacol; 1999 Sep; 128(1):27-34. PubMed ID: 10498831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
